Starling Oncology Warrant
STLNW
18 hedge funds and large institutions have $108K invested in Starling Oncology Warrant in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 15 → 18 (+3)
0.17% more ownership
Funds ownership: 5.55% → 5.72% (+0.17%)
87% less capital invested
Capital invested by funds: $827K → $108K (-$719K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FL
FreeGulliver LLC
New Orleans,
Louisiana
|
+$5.93K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$1.55K |
| 3 |
VF
Virtu Financial
New York
|
+$983 |
| 4 |
HF
HRT Financial
New York
|
+$856 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$678 |
Top Sellers
STLNW Hedge Fund Activity: Q2 2024 in Review
18 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q2 2024, worth a combined $108K — down 87% from $827K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new STLNW positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was FreeGulliver LLC, adding an estimated $5.93K.
- 18 institutional investors held Starling Oncology Warrant (STLNW) as of Q2 2024, up from 15 in Q1 2024.
- Funds reported $108K of Starling Oncology Warrant stock for Q2 2024, down 87% quarter-over-quarter.
- 3 funds opened new Starling Oncology Warrant positions in Q2 2024 and 0 closed out, a net change of +3 holders.
- The largest Starling Oncology Warrant buyer in Q2 2024 was FreeGulliver LLC, an estimated $5.93K added.
Based on aggregated 13F filings for Q2 2024.